EMMAC Life Sciences Limited is Europe's largest vertically integrated independent cannabis company. Based in the UK, the company has operations spanning cultivation, EU-GMP processing, distribution, and research and development across various European markets, including the UK, Germany, Italy, Spain, and Portugal. EMMAC's cultivation facility in Portugal is a leader in cost-effective cannabis flower production.
The company exports cannabis grown in Portugal to the Israeli market and plans to significantly increase its production capacity, aiming to exceed 10 tons per year by 2022. In the UK, EMMAC has witnessed substantial growth in the number of medical cannabis patients, with a 40% average monthly increase over the last six months as of December 2020.
In March 2021, EMMAC was acquired by Curaleaf Holdings, a leading US-based cannabis company, for a base consideration of approximately USD 286 million. The acquisition provided Curaleaf with a platform to enter the European cannabis market and positioned the combined entity as a global leader in the cannabis industry.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.